astrazeneca-sign

AstraZeneca’s Imfinzi meets endpoint at Phase 3 interim analysis in extensive-stage small cell lung cancer

pharmafile | June 27, 2019 | News story | Research and Development AstraZeneca, Imfinzi, pharma 

AstraZeneca has lifted the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage small cell lung cancer (SCLC), illustrating that the therapy met its primary endpoint in a planned interim analysis carried out by an independent data monitoring committee.

The results of the analysis demonstrated that use of Imfinzi, combined with standard-of-care etoposide and platinum-based chemotherapy in the first-line setting, led to a “statistically significant and clinically meaningful” improvement in overall survival (OS) compared to chemotherapy alone.

Following this analysis, the trial will now continue to further assess the impact on OS in combination with tremelimumab and chemotherapy.

The condition SCLC is an area with significant unmet need, and patients only have access to a handful of treatment options, making these results all the more impactful for affected patients.

“The Phase 3 CASPIAN results offer new hope for patients who are facing the devastating diagnosis of small cell lung cancer, and for whom new medicines are urgently needed,” commented José Baselga, Executive Vice President, Oncology R&D at AstraZeneca. “This is the first trial offering the flexibility of combining immunotherapy with different platinum-based regimens in small cell lung cancer, expanding treatment options.”

The company also announced that it will present these findings in full at an upcoming medical meeting.

Matt Fellows

Related Content

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …

Latest content